
Opinion|Videos|December 23, 2024
Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
- The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.
Advertisement
Video content above is prompted by the following:
- Cognition data was examined in the CLARIFY-MS extension study in patients 4 years after initial dose of cladribine. Please discuss changes in Symbol Digit Modalities Test (SDMT) scores over time and what these results mean for the cognitive function of the patient.
- What are your impressions of long-term cognition data with other high-efficacy therapies?
- How do you utilize cognitive data in your practice?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NSGC Poster Highlights Positive Impacts of Genetic Counseling for Individuals At-Risk for Frontotemporal Dementia
2
Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation
3
Real-World Oxybate Use in Narcolepsy, Tolerability and Reduced Stimulant Dependence
4
ALS Qualitative Study Highlights Complexities of Decision-Making Process for Medical Aid in Dying (MAID)
5




































